hepatocellular carcinoma
Conditions
Interventions
Observatoional group:transarterial therapiescombined with donafenib and Anti-PD-1 Antibody
Sponsors
Zhujiang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Clinically or histopathologically diagnosed HCC; 2. Not suitable for curative surgery, or local ablation; 3. Age 18~75 years; 4. Barcelona Clinic Liver Cancer (BCLC) Stage-B or C HCC; 5. Child–Pugh score A or B7; 6. Eastern Cooperative Group (ECOG) performance status <= 1; 7. No serious heart, lung, or renal dysfunction; 8. At least 1 measurable lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST).
Exclusion criteria
Exclusion criteria: 1. Comorbidity with other severe systemic diseases 2. Life expectancy is less than 3 months; 3. Discontinuation of treatment for personal reasons or inability to tolerate; 4. Incomplete data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate;Progression Free Survival;Overall Survival;Duration of Response;Adverse Event; | — |
Countries
China
Contacts
Public ContactMingxin Pan
Zhujiang Hospital of Southern Medical University
Outcome results
None listed